Pharmacological management of uterine leiomyoma

Uterine leiomyoma (ULM) as the most common benign tumor of the reproductive system still occupy second place (inflammatory diseases of the pelvic organs) in the structure of gynecological morbidity conditions. Prevalence of ULM is high and you cannot see a reducing trend anywhere. Over the past few decades a variety of drugs that target hormone-dependent tumors have been proposed. However, neither of drugs of pharmacological management can cure ULM. Hysterectomy remains to be the only radical curative agent. Effective management of ULM drug therapy is absolutely justified, especially in young women who want to preserve fertility. However, development of new drugs with minimal side effects remains to be currently central.